MA53743A - METHODS AND COMPOSITIONS FOR TREATING DISORDERS RELATED TO AGING USING CCR3 INHIBITORS - Google Patents
METHODS AND COMPOSITIONS FOR TREATING DISORDERS RELATED TO AGING USING CCR3 INHIBITORSInfo
- Publication number
- MA53743A MA53743A MA053743A MA53743A MA53743A MA 53743 A MA53743 A MA 53743A MA 053743 A MA053743 A MA 053743A MA 53743 A MA53743 A MA 53743A MA 53743 A MA53743 A MA 53743A
- Authority
- MA
- Morocco
- Prior art keywords
- aging
- compositions
- methods
- disorders related
- treating disorders
- Prior art date
Links
- 102100024167 C-C chemokine receptor type 3 Human genes 0.000 title 1
- 101710149862 C-C chemokine receptor type 3 Proteins 0.000 title 1
- 230000032683 aging Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Psychiatry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862737017P | 2018-09-26 | 2018-09-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA53743A true MA53743A (en) | 2022-01-05 |
Family
ID=69953286
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA053743A MA53743A (en) | 2018-09-26 | 2019-09-25 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS RELATED TO AGING USING CCR3 INHIBITORS |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP3856195A4 (en) |
| JP (2) | JP7528065B2 (en) |
| KR (1) | KR20210065950A (en) |
| CN (1) | CN112789044A (en) |
| AU (1) | AU2019346456A1 (en) |
| BR (1) | BR112021004938A2 (en) |
| CA (1) | CA3111433A1 (en) |
| CL (1) | CL2021000724A1 (en) |
| CO (1) | CO2021003713A2 (en) |
| EA (1) | EA202190463A1 (en) |
| IL (1) | IL281578A (en) |
| MA (1) | MA53743A (en) |
| MX (1) | MX2021002967A (en) |
| SG (1) | SG11202102105VA (en) |
| TW (1) | TW202027752A (en) |
| WO (1) | WO2020069008A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113166085B (en) | 2018-09-25 | 2024-04-09 | 安塔比奥公司 | Indane derivatives for treating bacterial infections |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200538098A (en) * | 2004-03-22 | 2005-12-01 | Astrazeneca Ab | Therapeutic agents |
| EP1996551A2 (en) * | 2006-03-07 | 2008-12-03 | AstraZeneca AB | Piperidine derivatives, their process for preparation, their use as therapeutic agents and pharmaceutical compositions containing them. |
| US8278302B2 (en) * | 2009-04-08 | 2012-10-02 | Boehringer Ingelheim International Gmbh | Substituted piperidines as CCR3 antagonists |
| PE20120810A1 (en) | 2009-04-22 | 2012-07-08 | Axikin Pharmaceuticals Inc | COMPOUNDS DERIVED FROM 5-CYANE-2- (PHENYLTHIUM) BENCENSULFONAMIDE AS ANTAGONISTS OF CCR3 |
| US20160208011A1 (en) * | 2010-01-28 | 2016-07-21 | The Board Of Trustees Of The Leland Stanford Junior University | Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same |
| UA109290C2 (en) | 2010-10-07 | 2015-08-10 | Common Crystals and Salts of CCR3 Inhibitors | |
| US20130261153A1 (en) * | 2012-04-03 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Use of ccr3-inhibitors |
| US10213421B2 (en) * | 2012-04-04 | 2019-02-26 | Alkahest, Inc. | Pharmaceutical formulations comprising CCR3 antagonists |
| MX394341B (en) * | 2017-04-05 | 2025-03-24 | Alkahest Inc | Methods and compositions for treating aging-associated impairments using ccr3-inhibitors |
| EP3606521B1 (en) * | 2017-04-05 | 2023-04-19 | Alkahest, Inc. | Compounds and pharmaceutical compositions for use in treating retina-associated disease using ccr3-inhibitors |
-
2019
- 2019-09-25 EA EA202190463A patent/EA202190463A1/en unknown
- 2019-09-25 MX MX2021002967A patent/MX2021002967A/en unknown
- 2019-09-25 EP EP19867321.2A patent/EP3856195A4/en active Pending
- 2019-09-25 KR KR1020217008493A patent/KR20210065950A/en not_active Withdrawn
- 2019-09-25 CA CA3111433A patent/CA3111433A1/en active Pending
- 2019-09-25 SG SG11202102105VA patent/SG11202102105VA/en unknown
- 2019-09-25 WO PCT/US2019/052995 patent/WO2020069008A1/en not_active Ceased
- 2019-09-25 MA MA053743A patent/MA53743A/en unknown
- 2019-09-25 BR BR112021004938-0A patent/BR112021004938A2/en not_active Application Discontinuation
- 2019-09-25 AU AU2019346456A patent/AU2019346456A1/en not_active Abandoned
- 2019-09-25 CN CN201980063258.7A patent/CN112789044A/en active Pending
- 2019-09-25 JP JP2021517342A patent/JP7528065B2/en active Active
- 2019-09-26 TW TW108134938A patent/TW202027752A/en unknown
-
2021
- 2021-03-17 IL IL281578A patent/IL281578A/en unknown
- 2021-03-23 CL CL2021000724A patent/CL2021000724A1/en unknown
- 2021-03-24 CO CONC2021/0003713A patent/CO2021003713A2/en unknown
-
2024
- 2024-07-24 JP JP2024118649A patent/JP2024153742A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7528065B2 (en) | 2024-08-05 |
| IL281578A (en) | 2021-05-31 |
| JP2022502441A (en) | 2022-01-11 |
| BR112021004938A2 (en) | 2021-06-01 |
| EP3856195A1 (en) | 2021-08-04 |
| TW202027752A (en) | 2020-08-01 |
| CO2021003713A2 (en) | 2021-04-08 |
| SG11202102105VA (en) | 2021-04-29 |
| AU2019346456A1 (en) | 2021-04-15 |
| KR20210065950A (en) | 2021-06-04 |
| WO2020069008A1 (en) | 2020-04-02 |
| CN112789044A (en) | 2021-05-11 |
| EP3856195A4 (en) | 2022-06-22 |
| MX2021002967A (en) | 2021-08-11 |
| EA202190463A1 (en) | 2021-06-29 |
| CL2021000724A1 (en) | 2021-10-15 |
| CA3111433A1 (en) | 2020-04-02 |
| JP2024153742A (en) | 2024-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2352517A4 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF COMPLEMENT RELATED DISORDERS | |
| EP3765094A4 (en) | GENE REGULATION COMPOSITIONS AND METHODS FOR IMPROVING IMMUNOTHERAPY | |
| EP3917539A4 (en) | COMPOSITIONS AND METHODS FOR TREATING NEUROCOGNITIVE DISORDERS | |
| EP3793566A4 (en) | COMPOSITIONS AND METHODS FOR REDUCING SPLICING DEFECTS AND TREATING RNA DOMINANCE DISORDERS | |
| MA54609A (en) | AZA-HETEROBICYCLIC MAT2A INHIBITORS AND METHODS OF USE FOR THE TREATMENT OF CANCER | |
| MA56050A (en) | HETEROBICYCLIC MAT2A INHIBITORS AND METHODS OF USE FOR THE TREATMENT OF CANCER | |
| MA54608A (en) | AZA-HETEROBICYCLIC MAT2A INHIBITORS AND METHODS OF USE FOR THE TREATMENT OF CANCER | |
| MA54880A (en) | COMPOSITIONS AND METHODS FOR TREATING NEUROCOGNITIVE DISORDERS | |
| EP3490366A4 (en) | METHODS AND COMPOSITIONS FOR THE EXPRESSION OF GENES IN PLANTS | |
| EP3799602A4 (en) | COMPOUNDS AND METHODS FOR REDUCING ATXN3 EXPRESSION | |
| EP4096439A4 (en) | COMPOSITIONS AND METHODS FOR TREATING DISORDERS RELATED TO AGING | |
| EP3368080A4 (en) | TREATMENT OF NERVOUS SYSTEM DISORDERS USING COMBINATIONS OF PXR AGONISTS AND THYROID HORMONES | |
| EP3793562A4 (en) | METHODS AND COMPOSITIONS FOR INHIBITING DIHYDROOROTATE DEHYDROGENASE | |
| MA53445A (en) | METHODS AND COMPOSITIONS FOR THE MODIFICATION OF PLANTS | |
| EP4045046A4 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF IRON-RELATED DISORDERS | |
| MA53234A (en) | MASP-2 INHIBITION COMPOSITIONS AND METHODS FOR TREATING VARIOUS THROMBOTIC DISORDERS AND DISEASES | |
| EP3924478A4 (en) | COMPOSITIONS AND METHODS FOR TREATING GLYCOGENOSIS TYPE 1A | |
| EP3813793C0 (en) | COMPOSITION FOR TREATING OCULAR HYPEREMIA AND METHOD FOR TREATING OCULAR HYPEREMIA USING SAME | |
| EP3701048A4 (en) | METHODS AND COMPOSITIONS FOR ASSESSING AND TREATING INTRAOCULAR DISEASES AND DISORDERS | |
| EP2349320A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF RENAL DISORDERS | |
| EP2453743A4 (en) | N-ACETYL CYSTEINE COMPOSITIONS AND METHODS FOR IMPROVING THE THERAPEUTIC EFFECTIVENESS OF ACETAMINOPHEN | |
| EP3735457A4 (en) | COMPOSITIONS AND METHODS FOR PRODUCING MEGACARYOCYTES | |
| EP3969041A4 (en) | COMPOSITIONS AND METHODS FOR TREATING T LYMPHOCYTE DEPLETION | |
| EP3801577A4 (en) | METHODS AND COMPOSITIONS INCLUDING TANKYRASE INHIBITORS FOR PRODUCING INSULIN-PRODUCING CELLS | |
| EP3737367A4 (en) | METHODS OF TREATING SOLID TUMORS USING CCR2 ANTAGONISTS |